Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Sunday, 08 August 2021 11:17

Michael Peled

Written by
Sunday, 08 August 2021 11:17

Tiberiu Shulimzon

Written by
Sunday, 08 August 2021 11:17

Amir Onn

Written by
Sunday, 08 August 2021 11:17

Iris Kamer

Written by
Sunday, 08 August 2021 11:17

Sameh Daher

Written by
Sunday, 08 August 2021 11:17

Aliza Ackerstein

Written by
Sunday, 08 August 2021 11:17

Ilanit Redinsky

Written by
Sunday, 08 August 2021 11:17

Damien Urban

Written by
Sunday, 08 August 2021 11:17

Jair Bar

Written by
Jair Bar is a Professor of Oncology at Tel Aviv University, and is the deputy director of the Institute of Oncology at the Sheba Medical Center, Israel. An MD with a PhD degree in molecular biology from the Weizmann Institute, he is an active physician-researcher. His training included a fellowship of Thoracic Oncology at the Ottawa Hospital Cancer Center in Ottawa, Canada. Dr Bar is involved in many clinical trials, translational studies and basic research of lung cancer. His research focuses mostly on deciphering mechanisms of resistance to immunotherapy in lung cancer patients, ex-vivo models of immunotherapy, and studies of immunotherapy in early stages of cancer. He is a member of the ISCORT, IASLC and ESMO. He was part of the initiative to form the Israel Lung Cancer Group, and its chairman during 2013-2021.
Sunday, 08 August 2021 11:17

Matt Evison

Written by
Dr Matthew Evison MD MRCP(Respiratory). Qualified from Manchester University Medical School in 2004. Undertook specialist training in Respiratory Medicine 2008-2014 including a two year fellowship in Thoracic Oncology at Wythenshawe Hospital, Manchester University NHS Foundation Trust, completing an MD degree in lung cancer diagnostics. Appointed as a Consultant in Respiratory Medicine (Thoracic Oncology) at Wythenshawe Hospital in 2014. Clinical Director for Lung Cancer for Greater Manchester Cancer and Clinical Lead for the Greater Manchester CURE Project (Hospital-based tobacco addiction treatment services). Chair of the British Thoracic Society Pleural Specialist Advisory Groups(SAG) and member of the tobacco SAG . Member of the British Thoracic Oncology Group Steering Committee and the NHS England Lung Cancer Expert Group.
Page 348 of 371